⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13632878 | 0.72 | — | — | |
| SCHEMBL7086753 | 0.67 | ALOX15 (0.46) | — | |
| SCHEMBL292267 | 0.67 | — | — | |
| Succinamide SCHEMBL36057 | 0.67 | — | — | |
| SCHEMBL6747830 | 0.67 | — | — | |
| Aminomethylamide SCHEMBL8299 | 0.67 | — | — | |
| Aminomethylamide SCHEMBL1354065 | 0.67 | OR51E2 (0.54) | — | |
| SCHEMBL4394 | 0.67 | — | — | |
| SCHEMBL3171034 | 0.67 | — | — | |
| SCHEMBL4395 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| EP-3004092-B1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| EP-2366705-A1 | Methods for synthesis of encoded libraries | Praecis Pharmaceuticals Incorporated (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2011079274-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2011-06-30 | — | — | WO | disclosed |
| EP-2027104-B1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2010-07-08 | — | — | US | disclosed |
| WO-2009137739-A1 | PROCESSES FOR THE PREPARATION OF O-[5-[4-AMINO-THIAZOL-2-YL]-PYRIDIN-2-YLMETHYL]-HYDROXYLAMINE | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2116267-A1 | Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for CEST applications | Bracco Imaging S.p.A (IT) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-1326856-B1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007053358-A2 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070104645-A1 | Chelate based scaffolds in tumor targeting | PARK FUNDING, LLC | 2007-05-10 | — | — | US | disclosed |